Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
about
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of thePoor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagementChanging Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.The Use of the Medical Dictionary for Regulatory Activities in the Identification of Mitochondrial Dysfunction in HIV-Infected Children.Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia.Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.High Viremia and Wasting Before Antiretroviral Therapy Are Associated With Pneumonia in Early-Treated HIV-Infected Kenyan Infants.Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of Congo
P2860
Q33650105-DEE68615-2BD7-41AE-AA04-69118C337EEAQ34212799-E5B136AD-3754-4BE5-A962-01F3C19F9890Q34374033-2799A452-4FA5-4D1D-B035-30E26ACB9022Q36311433-F8DF0510-AB45-46D5-B00F-7752B75BF1DEQ36929688-1D7085BE-4466-42FA-8948-6EB6E3614E89Q36948106-C8A06005-60EF-412A-A3BF-1E150CA169BEQ37356692-B183A2D4-383C-4EA0-AB71-8DFAF9757C4EQ37498812-1365296F-702C-4E5A-BB8C-C8B1A1852B23Q38873796-5CE22DC1-82E4-4B0E-9777-5C3F03D0CC24Q39535039-FF2A5DB5-5AC3-41FA-9414-0388E72CE078Q41381835-466C9C7F-43B5-4EA3-8A5D-158356B91CA7
P2860
Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Risk factors for opportunistic ...... active antiretroviral therapy.
@en
Risk factors for opportunistic ...... active antiretroviral therapy.
@nl
type
label
Risk factors for opportunistic ...... active antiretroviral therapy.
@en
Risk factors for opportunistic ...... active antiretroviral therapy.
@nl
prefLabel
Risk factors for opportunistic ...... active antiretroviral therapy.
@en
Risk factors for opportunistic ...... active antiretroviral therapy.
@nl
P2093
P1433
P1476
Risk factors for opportunistic ...... active antiretroviral therapy.
@en
P2093
George R Seage
Michael D Hughes
Nathalie Ylitalo
Pediatric AIDS Clincial Trials Group Protocol 219C Team
Russell Van Dyke
Sharon Nachman
Wayne Dankner
P304
P356
10.1001/ARCHPEDI.160.8.778
P407
P50
P577
2006-08-01T00:00:00Z